Clinical Trial

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this protocol is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that MK-8690 is superior to placebo with respect to the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-04-22
notable Trial sites expanded: 2 -> 7 locations 2026-04-22
Trial Details
NCT Number NCT07463183
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Colitis Ulcerative, Ulcerative Colitis
Enrollment 100 participants
Start Date 2026-03-24
Primary Completion 2027-10-28 (estimated)
Study Completion 2028-12-21 (estimated)
Updated on ClinicalTrials.gov 2026-07-31